AIRNA Appoints Jacob Elkins Chief Medical Officer
Cambridge, MA, USA and Tübingen, Germany, April 16, 2025 – AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, today announced the appointment of Jacob Elkins, M.D., as Chief Medical Officer. Dr. Elkins, an accomplished neurologist and biopharmaceutical executive, comes to AIRNA with two decades of leadership experience […]
AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline
Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new investors Current investors ARCH Venture Partners, Forbion Ventures, ND Capital, and others also participated AIRNA expected to file clinical trial application for Alpha-1 antitrypsin deficiency (AATD) RNA editing product candidate (AIR-001) with potential best-in-class […]
